Lipid Metabolism
A section of Metabolites (ISSN 2218-1989).
Section Information
Aims
The “Lipid Metabolism” section accepts manuscripts of original research and high-quality reviews on all aspects of lipid metabolism, including lipoproteins, with a particular focus on biomarkers of risk. This section accepts research papers on the clinical significance of plasma lipid and lipoprotein alterations in acute and chronic diseases, including obesity, diabetes, and cardiovascular disease, with special interest regarding alterations related to cardiometabolic risk. In addition, research papers on the therapeutic modulation of plasma lipids and lipoproteins, including the role of lifestyle, nutraceuticals, and drugs, are also welcome, with novel therapeutic approaches being of particular interest. Finally, this section welcomes the submission of International Consensus Documents.
Scope
Topics of interest include, but are not limited to:
- Identification of novel risk biomarkers
- The clinical significance of plasma lipid and lipoprotein alterations
- The evaluation of novel biomarkers in acute and chronic diseases
- The role of lifestyle and nutraceuticals
- The role of novel therapeutic approaches in treating metabolic disease
Editorial Board
Special Issues
Following special issues within this section are currently open for submissions:
- Advances in the Study of Lipids and Lipid Metabolism Based on Lipidomics (Deadline: 30 April 2024)
- Advances in Diagnosis and Treatment of Cardiovascular and Metabolic Diseases (Deadline: 30 April 2024)
- Mitochondria in the Lipid Metabolism (Deadline: 15 May 2024)
- Lipidomics as a Diagnostic Tool: Lipid Metabolism and Its Related Human Diseases (Deadline: 15 June 2024)
- Lipidomics in Health and Disease (Deadline: 30 June 2024)
- New Insights on the Role of Lipid Metabolism in the Development of Cardiac Dysfunction (Deadline: 1 August 2024)
- Lipid Metabolism and Cardiometabolic Diseases: Latest Advances and Prospects (Deadline: 30 September 2024)
- Lipid Biomarkers and Cardiometabolic Diseases (Deadline: 30 September 2024)
- Metabolic Syndrome and Non-alcoholic Liver Disease (Deadline: 20 October 2024)
- Lipidomic Signatures in Pediatric Metabolic Disorders (Deadline: 20 December 2024)